Thermo Fisher Scientific Stock News

Five corporate behemoths will report fourth-quarter 2021 earnings results next week. These are: TMO, FB, GOOGL, GILD and UPS.

Should investors be paying more attention to these health care stocks?

Thermo Fisher (TMO) is currently expanding its bioproduction purification resin capacity, which is used in the mRNA manufacturing process.

Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thermo Fisher Scientific is the world leader of life science products, analytical instruments, and diagnostic products. The company's growth trajectory is impressive considering its market cap is roug

With the emergence of the Omicron variant through the Q4 months globally, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered strong top-line contributions.

Pune, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Global Pharmaceutical & Biotechnology Environmental Monitoring Market Analysis and Insights : The global Pharmaceutical & Biotechnology Environmental Monitoring market size is projected to reach USD 1326.4 million by 2027, from USD 888 million in 2020, at a CAGR of 5.9% during 2021-2027 . Global " Pharmaceutical & Biotechnology Environmental Monitoring Market " Research Report provides vital evaluation accessible status of the Pharmaceutical & Biotechnology Environmental Monitoring with finest statistical data points, qualified feelings, definition, meaning, SWOT examination, and the most recent developments worldwide. It also includes estimates based on an acceptable set of expectations and processes. The research takes into account the revenue generated by This Report''s sales as well as improvements made by various application segments. The assessment report examines and provides information based on advertise segments such as geologies, applications, and industries.

Following an after-the-closing bell announcement yesterday of a development and co-marketing agreement with Thermo Fisher Scientific, shares of Oncocyte fell sharply today.

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH ) announced an upward revision to its 2021 net revenue guidance from 30 million Danish Krone to 40 million Danish Krone ($4.6 million - $6.1 million) to 35 million Danish Krone to 37 million Danish Krone ($5.3 million-$5.6 million). The company also narrowed its operating loss outlook. The company noted that the improved financial outlook for 2021 is mainly driven by increased visibility on net revenues from the use of arimoclomol in the Early Access Program in France and lower-than-expected operating expenses due to strict cost management. The stock was surging up 7.66% to $ 2.39 in premarket trading. Galapagos'' Filgotinib Gets U.K. Regulatory Nod For Treating Ulcerative Colitis Galapagos NV (NASDAQ: GLPG ) announced that the Medicines and Healthcare products Regulatory Agency has granted a marketing authorization for Jyseleca (filgotinib 200mg tablets), as a new treatment for ulcerative colitis in Great Britain.

Investors are optimistic about Thermo Fisher's (TMO) strong end-market growth and focus on international regions.